San Diego, CA (PRWEB) June 20, 2013
Resource4thePeople announced today its latest update for consumers who are following state and federal lawsuits alleging that women who used the popular contraceptive NuvaRing suffered serious blood-clotting side effects.
The first news is that the number of federal NuvaRing allegation lawsuits consolidated* before a single judge in U.S. District Court for the Eastern District of Missouri has climbed to 1,163, according to the latest statistics compiled by the United States Judicial Panel for Multidistrict Litigation.**
In addition, over 200 such state court cases are under the supervision of a judge in New Jersey Superior Court, where another multidistrict litigation*** is underway with the first trial was scheduled to begin this week.
“These figures demonstrate that there are large numbers of women who have allegedly suffered life-threatening blood-clotting problems as a result of their use of the popular contraceptive NuvaRing and are exercising their legal options,” said Resource4thePeople.
“As this litigation has progressed we have been receiving an increasing number of inquiries from consumers about the legal rights they may have to seek compensation for alleged side effects caused by the use of the NuvaRing. We will continue to provide free consultations for those consumers who are affected by these allegations.”
Resource4thePeople also is informing consumers that although there are multidistrict litigations involving consolidated lawsuits new cases are being accepted by Resource4thePeople’s national network of lawyers and new cases continue to be filed.
One of the most recent was filed in U.S. District Court, Southern District of Illinois**** on behalf of a man who filed a complaint in which he alleges his wife died after suffering a pulmonary embolism that his lawyers attribute to the use of a NuvaRing.
The lawsuit contains allegations that mirror those already consolidated in New Jersey and Missouri in which the plaintiffs are alleging that women suffered blood-clotting problems that caused pulmonary embolisms, deep vein thrombosis, stokes and other life-threatening side effects.
“The progress of these litigations shows that the judges are moving forward toward resolving these cases. As they do we will continue to answer inquiries from consumers about their eligibility to join in this litigation or file their own actions elsewhere and want to assure them that our national network of attorneys is continuing to accept cases involving alleged NuvaRing blood-clotting side effects.”
The cases that have been consolidated before Missouri U.S. District Judge Rodney Sippel involve common allegations that are summed up on the court’s multidistrict litigation web site and include the following language:
“NuvaRing is a prescription contraceptive device used by women throughout the United States. The individual plaintiffs in this matter claim that use of NuvaRing caused them injuries. They have filed suit in several state and federal courts alleging that the manufacturer of NuvaRing failed to adequately warn of the risks associated with the use of the product, and/or that the NuvaRing product is otherwise defective and unreasonably dangerous.” *
The information on the web site was posted after the Judicial Panel on Multidistrict Litigation consolidated the NuvaRing cases on August 22, 2008, and transferred the cases to Judge Sippel to conduct pretrial evidence-gathering for all of the cases.
The first bellwether trial from a pool of federal lawsuits involving claims that the NuvaRing puts women at higher risk of suffering blood clots than other contraceptives has been scheduled to begin in October.
Meanwhile, additional NuvaRing lawsuits involving similar allegations are being filed, and another of the most recent***** was filed by a Philadelphia woman who claims she suffered a venous sinus thrombosis and an intracranial hemorrhage last year.
In her lawsuit, the woman is claiming that those problems were caused by blood clotting caused by her use of a NuvaRing IUD over seven years. In her court filing, the woman said she has been forced to undergo a daily Coumadin regimen for her health problems, and suffers from depression and social anxiety.
Named as defendants are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.
The allegations cited in the multidistrict litigation claim that the NuvaRing, described by company officials as the first hormonal IUD, puts women at risk of suffering blood clots that can lead to life-threatening health problems because of the hormone mixture that prevents pregnancies.
The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.
On Oct. 27, 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis and pulmonary embolisms than women on birth control pills.******
Resource4thePeople also notes that NuvaRing has now posted warnings about the increased risks of suffering blood clots on the company’s web site under the heading of “IMPORTANT SAFETY INFORMATION.*****
- In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, U.S. District Court, Eastern District of Missouri
***In Re NuvaRing Litigation, Docket No. BER-L-3081-09, Bergen County, New Jersey Superior Court
****Case # 3:2013cv0335, U.S. District Court, Southern District of Illinois
***** Case No. 2:13cv0099, U.S. District Court for the Eastern District of Pennsylvania
******http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf FDA Oct. 27, 2011